Cambrian Biopharma
| File:Cambrian Biopharma company logo.png | |
| ISIN | 🆔 |
|---|---|
| Industry | Venture capital, pharmaceuticals |
| Founded 📆 | 2019[1] |
| Founders 👔 | James Peyer[2] Christian Angermayer[3] |
| Headquarters 🏙️ | New York, NY[4] |
Area served 🗺️ | |
Key people | James Peyer (CEO)[2] Christian Angermayer (Chairman) |
| Products 📟 | Research, development and funding for anti-aging drugs |
| Members | |
Number of employees | |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
Cambrian Biopharma ("Cambrian") is a New York City-based biotechnology investment company that invests in anti-aging research. The company studies the biological basis of aging, such as cellular wear and tear or mutations in DNA, and funds related treatments to slow the processes.[2]
History
Cambrian was co-founded in 2019 by James Peyer, a PhD in stem cell biology and former co-founder and managing partner at health-focused venture capital firm Apollo Ventures, along with billionaire investor and entrepreneur Christian Angermayer.[5][1][3] The company identifies and invests in new discoveries from university or other labs that target different causes or potential causes of aging.[6] The successful drugs would then be funded and spun off as standalone companies.[6] Peyer became the company's CEO, and Angermayer became Chairman.[7]
In October 2020, Cambrian and venture capital firm H&S Ventures co-led a $29 million funding round for bacteriophage cancer therapy company Sensei Biotherapeutics.[8] It was Cambrian's first portfolio company.[9]
In February 2021, Sensei Biotherapeutics began publicly trading with an IPO and raised $133 million at a valuation of $600 million.[7] Later in February, Cambrian exited Stealth mode and announced it had raised $60 million in private financing to develop medicines to extend lifespans.[7] In June, Cambrian led a $32 million Series A funding round for stem cell engineering company Vita Therapeutics, a spin off from Johns Hopkins.[10] It was Cambrian's second portfolio company.[9] In October, Cambrian secured a $100 million Series C funding round, intended to fund three to five clinical trials in the following 18 months.[3] The round was co-led by investment firm Anthos Capital and SALT Fund, an investment arm of SkyBridge Capital, with participation from existing backers Apeiron Investment, Future Ventures and Moore Capital.[3] At the time, CEO Peyer announced that the company expected to have 18 drug candidates by the end of 2021.[4]
In February 2022, Cambrian announced it had licensed rights to mTOR inhibitor programs from Swiss pharmaceutical corporation Novartis.[11] As part of the deal, Cambrian was setting up a subsidiary called Tornado Therapeutics.[11]
Business model
Cambrian researches and develops treatments to slow the effects of aging, to extend the number of years an individual can enjoy a healthy life.[2] It has identified 14 new therapies that are under development to treat and prevent diseases of aging.[1] Due to the difficulty of running clinical trials for anti-aging drugs, Cambrian identifies drugs that are promising candidates for aging diseases, finds a safe application of the drug for a current disease, and then once it is approved, applies for use for elderly patients to prevent the aging disease.[1]
As of 2021, Cambrian was focusing on three categories of aging: intracellular dysfunction, cellular dysfunction and tissue level dysfunction.[7] Its research includes muscle stem cell treatments for a rare form of childhood muscular dystrophy cancer.[9]
Spinouts
The following companies were funded and launched by Cambrian:
Operations
Cambrian is headquartered in New York City.[4] James Peyer is the company's CEO, and Christian Angermayer is the company's Chairman.[7] Former Allergan R&D Chief Brent Saunders sits on the Cambrian board.[3]
References
- ↑ 1.0 1.1 1.2 1.3 "The Startup That May Hold the Key to Extending Human Life". Bloomberg. October 26, 2021. Retrieved March 14, 2022.
- ↑ 2.0 2.1 2.2 2.3 "Silicon Valley is chasing the fountain of youth". Axios. September 25, 2021. Retrieved March 14, 2022.
- ↑ 3.0 3.1 3.2 3.3 3.4 "Cambrian secures $100M series C for Roivant-like approach to biotech creation with goal to slow down human aging". Fierce Biotech. October 26, 2021. Retrieved March 14, 2022.
- ↑ 4.0 4.1 4.2 "SoHo biotech raises $100M Series C to target age-related diseases". Crain's New York Business. October 27, 2021. Retrieved March 14, 2022.(subscription required)
- ↑ "Cambrian is Using a New Drug Discovery Model to Solve the Science of Aging". PM360. April 26, 2011. Retrieved March 14, 2022.
- ↑ 6.0 6.1 "Brent Saunders joins $100M Series C for a company out to be the BridgeBio of aging". Endpoints News. October 26, 2021. Retrieved March 14, 2022.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 "New York-based biotech raises $60 million to develop a pipeline of companies and therapeutics to treat diseases of aging under its unique operational strategy". Longevity Technology. February 9, 2021. Retrieved March 14, 2022.
- ↑ "Sensei raises $29M to advance anti-cancer bacteriophage pipeline". Fierce Biotech. October 9, 2020. Retrieved March 14, 2022.
- ↑ 9.0 9.1 9.2 "UPDATED: Can a cell therapy treat muscular dystrophy? A German billionaire's anti-aging startup is trying to find out". Endpoints News. June 24, 2021. Retrieved March 14, 2022.
- ↑ 10.0 10.1 "Cambrian spun off Baltimore stem cell startup Vita Therapeutics raises $32M". Baltimore Business Journal. June 23, 2021. Retrieved March 14, 2022.
- ↑ 11.0 11.1 11.2 "Novartis vet is getting another shot at mTOR following the implosion of a longevity pioneer". Endpoints. February 16, 2022. Retrieved March 14, 2022.
External links
This article "Cambrian Biopharma" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Cambrian Biopharma. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
